Skip to main content

Deepinder Pal Singh, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Radiation Oncology


Cancer is one of the most challenging medical problems, especially head and neck and lung cancers. I am very well trained, well read and highly experienced. I am also a compassionate and caring physician.

I provide my patients with comprehensive medical care including personalized, curative intent treatment. Since my patients deserve only the best, they can be confident knowing they will receive excellent medical care from me. My areas of expertise include stereotactic body radiation therapy and brachytherapy for lung cancers, as well as treating nasopharyngeal, oropharyngeal, oral cavity, laryngeal and hypopharyngeal cancers.

Conditions I Treat:

- Lung cancer
- Head and neck cancers



MBBS | Indira Gandhi Medical College, Shimla (India)

Post-doctoral Training & Residency

07/01/2005 - 06/30/2009
Residency in Radiation Oncology at University of Rochester Medical Center

07/01/2003 - 06/30/2005
Fellowship in Radiation Oncology at University of Rochester Medical Center

04/02/2001 - 06/30/2003
Fellowship in Research at University of Rochester Medical Center

09/17/1986 - 12/16/1989
Fellowship at Postgraduate Institute of Medical Education & Research

07/01/1984 - 06/30/1986
Residency at Postgraduate Institute of Medical Education & Research

05/23/1982 - 05/22/1983
Residency at Indira Ghandi Medical College (India)

05/08/1981 - 05/07/1982
Internship at Indira Ghandi Medical College (India)

VIEW ALL expand_more


Certificate of Appreciation
Sponsor: Department of Radiation Oncology Nurses
Location: Rochester, NY

2019 - 2020
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

2016 - 2019
Bronze Star
Sponsor: University of Rochester Medical Center
Location: Rochester, NY

2012 - 2013
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

VIEW ALL expand_more

Clinical Trials

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

Lead Researcher: Deepinder Pal Singh

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Standard chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, pemetrexed, and etoposide. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding SBRT to the standard treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with inoperable non-small cell lung cancer than giving the standard treatment alone.

View Study Details

Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early- Stage Non-Small-Cell Lung Cancer: A Prospective Randomized Phase II Study

Lead Researcher: Deepinder Pal Singh

This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be randomly assigned to either the 3 Fraction or 5 Fraction schedule of radiation. After patients complete radiation treatment, they will follow up with their radiation oncologist.

View Study Details


Journal Articles

Oliver DE; Laborde JM; Singh DP; Milano MT; Videtic GM; Williams GR; LaRiviere MJ; Chan JW; Peters GW; Decker RH; Samson P; Robinson CG; Breen WG; Owen D; Tian S; Higgins KA; Almeldin D; Jabbour SK; Wang F; Grass GD; Perez BA; Dilling TJ; Strosberg J; Rosenberg SA. "Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience". Int J Radiat Oncol Biol Phys. 2023; 116(4): 849-857.

Hardy SJ, Bandyopadhyay S, Yang H, Williams A, Gudina A, Cummings MA, Zhang H, Singh DP, Chen Y, Mohile NA, Janelsins MC, Milano MT. "Stroke death in patients receiving radiation for head and neck cancer in the modern era." Frontiers in oncology.. 2023 13:1111764. Epub 2023 Jun 15.

Bergsma D; Moravan MJ; Suri JS; Cummings MA; Usuki KY; Singh DP; Milano MT. "Patterns of recurrence after intracranial stereotactic radiosurgery for brain-only metastases from non-small cell lung cancer and the impact of upfront thoracic therapy with synchronous presentation". J Thorac Dis. 2022; 14(6): 1869-1879.

Books & Chapters

Chapter Title: Translational Research in Lung Cancer
Book Title: Advances in Radiation Oncology in Lung Cancer
Author List: Singh D; Bylund K; Chen Y
Edited By: Jeremic B
Published By: Springer-Verlag GmbH 2011 in Heidelberg

Chapter Title: Carcinoma of the nasopharynx
Book Title: Textbook of Radiation Oncology: Principles and Practice
Author List: Sharma SC, Singh DP, Jalali R
Published By: Churchill Livingstone 2000



At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.